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Background. There is evidence that bipolar disorder (BD) is associated with signiﬁcant neurocognitive deﬁcits and
this occurs in individuals with BD type I (BD I) and with BD type II (BD II). Only a few studies have focused on
cognitive impairment in BD II. The aim of this study was to describe the pattern of cognitive impairment in patients
with BD II, in order to identify speciﬁc cognitive deﬁcits that distinguish BD II from BD I patients as well as from
healthy subjects.
Method. We performed a systematic review of the literature of neuropsychological studies of BD II published
between 1980 and July 2009. Fourteen articles fulﬁlled the inclusion criteria and were included in this review.
Results. Main cognitive deﬁcits found in BD II include working memory and some measures of executive functions
(inhibitory control) and approximately half of the studies also detected verbal memory impairment.
Conclusions. There are subtle diﬀerences between the two subtypes regarding cognition. This may suggest
neurobiological diﬀerences between the two subgroups which will be helpful in order to determine cognitive
endophenotypes in BD subtypes.
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Introduction
Bipolar disorder (BD) occurs in multiple forms and
degrees of severity. Whereas the Diagnostic and
Statistical Manual of Mental Disorders (DSM-IV) in-
cludes the BD II subtype, the International Classiﬁ-
cation of Diseases, 10th Revision (ICD-10) does not
recognize it as a speciﬁed nosological category (Vieta
& Suppes, 2008).
The clinical course of BD II is characterized by the
presence or history of one or more major depressive
episodes and at least one hypomanic episode lasting
at least 4 days (APA, 2000). It is often initially mis-
diagnosed as unipolar depression, adjustment dis-
order or personality disorder (Berk & Dodd, 2005).
Many clinicians still consider BD II as a mild form of
classical BD, although the data indicate that it may be
associated with high morbidity and mortality, includ-
ing higher episode frequency, co-morbidity, suicidal
behaviour and rapid cycling as compared with BD I
(Vieta et al. 1997, 1999). Misdiagnosing BD II may also
aﬀect therapeutic decisions and therefore the course
and prognosis of bipolar patients (Vieta & Suppes,
2008). An early age at onset of BD II has been asso-
ciated with a higher degree of severity, a poorer
treatment response and a worse prognosis (Engstrom
et al. 2003).
The estimated prevalence of BD II is from 0.5% to
6% depending on the ﬂexibility of the application
of diagnostic criteria (Akiskal, 1996 ; Angst, 1998 ;
Benazzi, 1999).
In the past, several reviews have been published
supporting recognition of BD II as a distinct category
within mood disorders (Vieta & Suppes, 2008).
Emerging evidence suggests considering cognitive
impairment as a trait marker in BD, this impairment
being present even during euthymic periods. Recently
published meta-analyses have shown that executive
functions and verbal memory are the most impaired
cognitive domains in euthymic patients (Robinson
et al. 2006 ; Torres et al. 2007) as well as attention/
processing speed (Torres et al. 2007). These neurocog-
nitive deﬁcits have been postulated to constitute trait
markers or endophenotypes of BD (Glahn et al. 2004 ;
Savitz et al. 2005), but the speciﬁc neurocognitive and
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therefore endophenotypic status of BD II and other
bipolar spectrum disorders remains unclear (Savitz
et al. 2008). Moreover, the concept of allostatic load is
interesting in order to explain cognitive impairment in
BD. The increased allostatic load in bipolar patients
may be related to the cognitive decline seen among
such patients as well as other pathophysiological
mechanisms involved in illness progression. The main
mediators of allostatic load are the dysregulation of
the hypothalamic–pituitary–adrenal axis, and altered
immunity, pro-inﬂammatory and oxidative stress
states (Kapczinski et al. 2008).
Only a few studies have focused on cognitive im-
pairment in BD II, probably due to the fact that BD II is
an underdiagnosed entity. Most data regarding neuro-
cognition in BD come from studies focusing on BD I
patients or mixed samples of BD I and BD II subjects.
In one of the ﬁrst studies comparing BD I and BD II,
euthymic BD II patients had signiﬁcantly less insight
and higher level of subjective cognitive complaints
than BD I patients (Pallanti et al. 1999). It is noteworthy
that cognitive impairment, particularly memory deﬁ-
cits, may have negative implications in the functional
outcome of bipolar patients (Martı´nez-Ara´n et al.
2004a, b). Between 30% and 50% of patients with BD
experience signiﬁcant social disability that may be re-
lated to persistent cognitive impairment (Zarate et al.
2000) and there is a paucity of studies focusing on this
topic in BD II.
The main aim of this critical review is to examine
the existing literature on cognitive impairment in BD II
in order to identify speciﬁc cognitive deﬁcits that dis-
tinguish BD II from BD I patients, as well as from
healthy subjects, therefore having implications for the
patho-aetiology and nosology of this disorder.
Methodology
A comprehensive PubMed/Medline search was car-
ried out in order to conduct an objective review of the
available literature on the neuropsychology of BD II.
The search was supplemented by manually reviewing
reference lists from the identiﬁed publications. Only
English-language articles published from 1980 to July
2009 were included in the present paper, using the
search term ‘bipolar II ’ cross-referenced with ‘cog-
nition’, ‘cognitive function’, ‘cognitive impairment ’,
‘neuropsychological ’, ‘neuropsychological function’,
‘neurocognitive ’, ‘attention’, ‘memory’, ‘executive
function’ and ‘ intellectual function’. Eligibility criteria
were : (a) studies that included a comparison group
[psychiatric or healthy control (HC) group] or norma-
tive data for standardized tests ; (b) groups formed of
more than 10 BD II subjects ; (c) published between
1980 and July 2009; (d) adult patients (aged 18–65
years) ; (e) the use of standardized diagnostic criteria,
such as DSM; (f) selection of standardized or well-
established cognitive tasks ; and (g) provided clear
descriptive and comparative statistics of cognitive
function measures.
Results
The systematic search yielded 55 articles, out of which
15 fulﬁlled the inclusion criteria. Table 1 summarizes
the ﬁndings of the studies included in this review.
Results will be shown according to diﬀerent neuro-
cognitive domains.
General intellectual function
One of the selected studies did not assess pre-morbid
intelligence quotient (IQ) or current IQ (Hsiao et al.
2009). Most of the other studies did not ﬁnd signiﬁcant
diﬀerences between BD I, BD II and the HC group in
the estimated current IQ, using diﬀerent subtests of
the Wechsler Adult Intelligence Scale or the Wechsler
Abbreviated Scale of Intelligence (WASI), or the pre-
morbid IQ using the National Adult Reading Test
(NART) (Torrent et al. 2006 ; Taylor Tavares et al. 2007;
Andersson et al. 2008 ; Holmes et al. 2008 ; Savitz et al.
2008). Harkavy-Friedman et al. (2006) did not ﬁnd
signiﬁcant diﬀerences in estimated current IQ as-
sessed by the Peabody Picture Vocabulary either. It is
noteworthy that Simonsen et al. (2008) did not ﬁnd any
diﬀerence between the three groups (BD I, BD II and
HC) in pre-morbid IQ assessed by the NART; how-
ever, current IQ assessed by the WASI revealed that
the mean score of BD I patients was lower than that of
the HC group, whilst BD II patients did not diﬀer sig-
niﬁcantly from either group. However, although these
diﬀerences were statistically signiﬁcant, they were not
signiﬁcant from a clinical point of view.
Only one study found that both BD I and BD II
patient groups diﬀered signiﬁcantly from the HC
group as to pre-morbid IQ, but they did not diﬀer
signiﬁcantly one from another (Dittmann et al. 2008).
The baseline diﬀerences in pre-morbid IQ among
groups might have aﬀected the results on neuro-
psychological performance.
Furthermore, only one study considered an index of
IQ change in order to assess intellectual decline and
found that BD II patients scored signiﬁcantly lower
than BD I on full-scale IQ change (Summers et al.
2006). Bruno et al. (2006), using the same sample of BD
patients, aimed to correlate cognitive performance
(IQ change) with structural brain abnormalities using
neuroimaging techniques. An association between
fronto-temporal abnormalities and decline in IQ in BD
was detected as well as that the structural/cognitive
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Table 1. Studies on neurocognition including patients with BD II
Authors Sample Cognitive measures Results Comments
Berns et al. (2002) 13 BD II v. 14 HC RT task (novel spatial–motor sequence) BD II=HC in RT
Diﬀerences in brain activation, BD II
reacted biologically in a way
congruent with aﬀective lability
Lack of parietal activation in patients ;
widespread medial prefrontal and limbic
activation
Martı´nez-Aran
et al. (2004a)
108 BD (30 D v.
34 M v. 44 E) v.
30 HC
WAIS Voc ; WCST, SCWT, FAS, Animal Naming ;
WAIS digits, TMT-A TMT-B ; CVLT, WMS-R
Logical Memory, WMS-R Visual Reproduction
BD I<BD II : CVLT No diﬀerentiation in clinical status in the
analysis of diagnostic subtype
Bruno et al. (2006) 11 BD II v. 25 BD I IQ NART; IQ WAIS-R ; Recognition Memory Test,
PALT, ROCFT, Doors and People Test ; MCST;
SWM, IDED of CANTAB
Structural/cognitive correlates more
extensive in BD II than BD I Same sample as in Summers et al. (2006)
study.
Structural brain abnormalities were
correlated with decline in IQ. They also
explored diﬀerences between clinical
subtypes
Harkavy-
Friedman et al.
(2006)
19 BD II v. 32 BD I
v. 58 HC
PPVT; Finger Tapping Test, Brief Computerized
RT; WAIS-III Digit Symbol, TMT-A, TMT-B ;
Buschke Selective Reminding Test, BVRT; CPT,
Stroop ; N Back Test, A not B RT; Go-No-Go,
Time Estimation Test ; FAS
BD I, BD II<HC: Digit Symbol, N Back
Test, Go-No-Go
BD II<HC: A not B RT, FAS
(BD I=BD II, HC)
BD II<HC, BD I : RT, Stroop
Patients in a depressive episode with
suicide attempt
Summers
et al. (2006)
11 BD II v. 25 BD I IQ NART, IQ WAIS ; Recognition Memory Test,
PALT, ROCFT, Doors and People Test ; TMA-A;
Graded Naming Test ; MCST, SCWT, COWAT,
Hayling Sentence Completion Test, CANTAB
SWM and IDED Set-Shift, TMT-B ; Emotional
expression multimorph task
BD I, BD II : impaired in recognition of
surprise
BD II<BD I : IQ change, memory
(RMF, PALT1, ROCFT) and executive
functions (TMT-B, SWM)
BD I : impaired in verbal recognition,
SWM
BD II : impaired verbal recognition,
SWM, recognition for faces, shape test,
ROCFT, PALT1, Heyling Sentence Test,
Stroop, IDED set-shift
Nine patients had a current depressive
episode (no diﬀerences between subtypes
BD I v. BD II). No patients with current
manic/hypomanic episode. The eﬀects of
depressive symptomatology were
controlled for
Torrent et al.
(2006)
33 BD II v. 38 BD I
v. 35 HC
WAIS Voc ; WCST, SCWT, FAS, Animal Naming ;
WAIS Digits, TMT-A, TMT-B ; CVLT
BD I<BD II<HC: CVLT, SCWT
BD I, BD II<HC: attention (TMT-A,
digits forward), WM (digit backward)
Euthymic patients during 6 months
(HAMDf8, YMRSf6)
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Table 1 (cont.)
Authors Sample Cognitive measures Results Comments
Taylor Tavares
et al. (2007)
17 BD II v. 22
MDD v. 25 HC
WASI : CANTAB (PRM, SRM, SSP, SMTS &
DMTS, SWM, IDED) ; CGT; IST
BD II=HC: on all neuropsychological
measures
MDD<HC: SWM, IST
EDS (IDED)
MDD<BD II : CGT (quality of decision
after a loss trial)
Unmedicated depressed patients during
3 weeks (8 weeks for ﬂuoxetine)
Andersson et al.
(2008)
25 BD II v. 28 HC WASI Voc, Matrices ; PASAT; SCWT, FAS ;
CVLT-II ; ROCFT; WAIS-R Digit Symbol ERP
BD II<HC: on all neuropsychological
measures except FAS
BD II>HC: MMN latency
Euthymic patients or middle to moderate
depressed patients.
Authors assessed neurocognitive
functioning combining neuropsychological
test and ERP
Dittmann et al.
(2008)
38 BD II v. 65 BD I
v. 62 HC
HAWIE-R Information ; RBANS Form-A; TMT-A,
TMT-B ; WAIS-III Letter–Number Sequencing
BD I<HC: on all domains except
visual/constructional abilities
BD II<HC: psychomotor speed, WM,
visual/constructional abilities and
executive functions
BD I=BD II ; on all domains
Euthymic patients (at least 1 month).
Results supported a similar
neuropsychological proﬁle in both
subtypes
Holmes et al.
(2008)
33 Medicated BD
(6 BD I, 27 BD II)
v. 32
unmedicated BD
(7 BD I, 25 BD II)
v. 52 HC
IQ WASI ; CANTAB (RVP, PRM, SWM)
Aﬀective Shift Task
Medicated BD, particularly BD II :
deﬁcits on aﬀective processing
(positive) and sustained
attention (RVP)
Medicated BD=unmedicated
BD=HC: PRM, SWM
Patients tested during depressed mood
states.
Additional tests omitting BD I patients to
determine the impact of this smaller group
on the overall results
Savitz et al. (2008) 19 BD II v. 49 BD I
v. 44 MDD-R v.
33 MDD-S v. 20
other DSM-IV v.
65 unaﬀected
relatives
SA-WAIS General Knowledge ; Digits ; COWAT,
WCST, SCWT; ROCFT; RAVLT
BD I<unaﬀected relatives : RAVLT
BD II=unaﬀected relatives
Patients tested in a euthymic or at least
relatively euthymic state (Beck Depression
Inventory<10, ASRM<6).
Assessment of neuropsychological
performance while controlling for
childhood trauma, alcohol abuse and
medication
Simonsen et al.
(2008)
31 BD II v. 42 BD I
v. 124 HC
IQ NART, IQ WASI ; WMS-III logical memory,
CVLT-II ; WAIS-III Digits, WM-MA; D-KEFS
Verbal Fluency ; D-KEFS Colour-Word
Interference Test
BD I<BD II, HC: logical memory,
CVLT
BD I<HC: digits backward, ﬂuency
set-shifting
BD I, BD II<HC: WM-MA, phonetic
ﬂuency, Colour-Word Interference
Test
Excluded severely depressed or severely
manic patients
24% BD I and 13% BD II had clinically
signiﬁcant cognitive impairment (f1.5 S.D.)
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Derntl et al. (2009) 36 BD II v. 26 BD I
v. 62 HC
SPM; VERT-K; VIEMER-K BD I<HC: SPM, VERT-K
BD II>HC: VIEMER-K
Euthymic patients or with residual aﬀective
symptoms (MADRS<18). Two patients
with YMRS>8
Simonsen et al.
(2011)
102 SZ v. 27 SZA
v. 80 BD I v. 56
BD II v. 280 HC
NART-IQ; WMS-III Logical Memory, CVLT-II ;
WAIS-III Digit Symbol ; Digits, WM-MA;
D-KEFS Verbal Fluency ; D-KEFS Colour-Word
Interference Test
Diagnostic subtype only aﬀects two
verbal recall measures (WMS-III
logical memory, CVLT-II)
Authors investigated the role of lifetime
history of psychosis for neurocognitive
functioning. History of psychosis explained
the neurocognitive variance in BD better
than diagnostic subtype
Hsiao et al. (2009) 37 BD II v. 30 BD I
v. 22 HC
WMS-III (Logical Memory I and II ; VPA I and II,
Faces I and II, Family Pictures I and II, Digit Span,
Spatial Span) ; WAIS-III Digit Symbol, TMT-A;
TMT-B
BD I<BD II, HC: WMS-III, TMT-B
BD I=BD II=HC: Visual Memory,
TMT-A
BD I, BD II<HC: WM
BD I<BD II<HC: Digit Symbol
Patients in an interepisode state (HAMDf7,
YMRSf6) for at least 1 week before the
assessment.
Using Memory Index for WMS-III.
Pre-morbid IQ was not estimated
ASRM, Altman Self-Rating Mania Scale ; BD, bipolar disorder ; BD I, bipolar disorder type I ; BD II, bipolar disorder type II ; BVRT, Benton Visual Retention Test ; CANTAB, Cambridge
Neuropsychological Test Automated Battery ; CGT, Cambridge Gamble Test ; COWAT, Controlled Oral Word Association Test ; CPT, Continuous Performance Test ; CVLT, California
Verbal Learning Test ; D, depressed patients ; D-KEFS, Delis Kaplan Executive Functioning Scale ; DSM, Diagnostic and Statistical Manual of Mental Disorders ; E, euthymic patients ; EDS,
Extra-Dimensional Shift ; ERP, event-related potentials ; FAS, letter ﬂuency test ; HAWIE-R, German version of WAIS-R Information ; HC, healthy controls ; HAMD, Hamilton Depression
Rating Scale ; IDED, Intra-Dimensional Extra-Dimensional Set Shifting ; IQ, intelligence quotient ; IST, Information Sampling Test ; M, manic or hypomanic patients ; MADRS, Montgomery
Asberg Depression Rating Scale ; MCST, Modiﬁed Wisconsin Card Sorting Test ; MDD, major depressive disorder ; MDD-R, major depressive disorder – recurrent ; MDD-S, major
depressive disorder – single ; MMN, mismatch negativity ; NART, National Adult Reading Test ; PALT, Paired Associates Learning Test (Warrington, 1996) ; PASAT, Paced Auditory
Serial Addition Test ; PPVT, Peabody Picture Vocabulary Scores ; PRM, Pattern Recognition Memory ; RAVLT, Rey Auditory Verbal Learning Test ; RBANS, Repeatable Battery for the
Assessment of Neuropsychological Status ; RMF, Recognition Memory Faces ; ROCFT, Rey-Osterreich Complex Figure Test ; RT, reaction time ; RVP, Rapid Visual Information Processing ;
SA-WAIS, South African-Wechsler Adult Intelligence Scale ; SCWT, Stroop Colour-Word Test ; S.D., standard deviation ; SMTS & DMTS, Simultaneous and Delayed Matching to Sample ;
SPM, Ravens’s Standard Progressive Matrices ; SRM, spatial recognition memory ; SSP, spatial span ; SWM, spatial working memory ; SZ, schizophrenia ; SZA, schizo-aﬀective ; TMT-A,
Trail Making Test A; TMT-B, Trail Making Test B ; VERT-K, Vienna Emotion Recognition Tasks ; VIEMER-K, Vienna Memory of Emotion Recognition ; VPA, Verbal Paired Associates ;
WAIS-R, Wechsler Adult Intelligence Scale – Revised ; WASI, Wechsler Abbreviated Scale of Intelligence ; WCST, Wisconsin Card Sorting Test ; WM, working memory ; WM-MA,
Working Memory-Mental Arithmetic Test ; WMS, Wechsler Memory Scale ; YMRS, Young Mania Rating Scale.
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correlates were more extensive in BD II than in BD I
patients. The authors hypothesized that persistent
depression, rather than mania, may represent a key
pathophysiological factor or, alternatively, that BD II
represents a clinical phenotype at risk for developing
cognitive abnormalities. Although it is not possible to
know whether the neuroanatomical substrate of cog-
nitive function in patients deviates from that of normal
subjects since the study did not include HCs, this does
not invalidate the detection of diﬀerences between
the two subgroups of BD patients. Moreover, the BD II
sample was small (n=11).
In conclusion, most studies failed to detect signiﬁ-
cant diﬀerences in the IQ of BD II patients compared
with BD I patients or healthy subjects.
Attention and psychomotor speed
In the selected studies attention and psychomotor
speed have been assessed by diﬀerent tests [Trail
Making Test (TMT), Digits Span, Digit Symbol, Stroop
Test, simple reaction time, Continuous Performance
Test (CPT), Coding Task in RBANS (Repeatable
Battery for the Assessment of Neuropsychological
Status), Rapid Visual Information Processing from
the Cambridge Neuropsychological Test Automated
Battery (CANTAB)]. In three studies euthymic BD II
patients were found to have poorer performance
compared with HCs (Torrent et al. 2006 ; Andersson
et al. 2008 ; Dittmann et al. 2008), as well as BD I
patients ; there were no diﬀerences between these two
groups (Torrent et al. 2006 ; Dittmann et al. 2008). In
another more recent study BD II patients in an inter-
episodic phase had an intermediate performance be-
tween BD I and healthy subjects (Hsiao et al. 2009). In a
study (Harkavy-Friedman et al. 2006) assessing BD
patients with a depressive episode, BD II patients had
a worse performance in the Digit Symbol subtest, and
performed worse than BD I patients in the Stroop Test.
However, no signiﬁcant diﬀerences were found in the
TMT Test A (TMT-A) and CPT; this is the only study
that assessed sustained attention by means of the
CPT. Holmes et al. (2008) detected deﬁcits in sustained
attention in depressed medicated BD patients, par-
ticularly those with BD II, but not unmedicated BD
patients, and suggested that such attention impair-
ment may be speciﬁcally related to treatment with
mood-stabilizing agents, therefore representing a
medication side-eﬀect or being the combination of the
two.
On the other hand, two studies did not ﬁnd im-
paired attention using the Digits Forward (Savitz
et al. 2008 ; Simonsen et al. 2008) and three of them
did not ﬁnd impairment in psychomotor speed
using the TMT-A with respect to HC subjects
(Harkavy-Friedman et al. 2006 ; Hsiao et al. 2009) or
with respect to normative data (Summers et al. 2006).
Hence, concerning this domain the results are con-
tradictory, probably due in part to the attentional
measures used. Most measures implicate other com-
ponents such as working memory and psychomotor
speed, which may be less sensitive. In this regard, only
one of the studies used the CPT, a widespread
measure of sustained attention.
Learning and memory
Verbal memory
Verbal memory is usually evaluated with tests in-
cluding word lists and story recall.
In four out of nine studies, BD II patients scored
signiﬁcantly worse than control subjects or normative
data in this domain (Martı´nez-Ara´n et al. 2004b ;
Summers et al. 2006 ; Torrent et al. 2006; Andersson
et al. 2008) and two of them showed that the BD I
group performed worse on some measures of verbal
memory than the BD II group (Martı´nez-Ara´n et al.
2004a ; Torrent et al. 2006). Of these reports, only the
study conducted by Torrent et al. (2006) assessed ex-
clusively euthymic patients. In the study by Summers
et al. (2006) BD I patients were only impaired in verbal
recognition memory, whereas BD II patients presented
more impairment in verbal memory measures. The
small sample size of the BD II group (n=11) should,
however, be taken into account.
In contrast, deﬁcits in verbal memory in BD II
patients were not found in ﬁve studies (Harkavy-
Friedman et al. 2006 ; Dittmann et al. 2008; Savitz et al.
2008 ; Simonsen et al. 2008; Hsiao et al. 2009), whereas
in four of them a signiﬁcantly worse performance in
BD I patients was observed (Dittmann et al. 2008 ;
Savitz et al. 2008 ; Simonsen et al. 2008 ; Hsiao et al.
2009). However, Harkavy-Friedman et al. (2006) did
not ﬁnd signiﬁcant diﬀerences between BD I and BD II
patients with a depressive episode and suicide at-
tempts and HCs.
Simonsen et al. (2011) investigated whether neuro-
cognitive dysfunction depends more on the history of
psychosis or the diagnostic subtype and found that the
latter only had signiﬁcant main eﬀect on two verbal
recall measures, whereas history of psychosis inﬂu-
enced all subscores.
Discrepancies between studies do not allow us to
draw conclusive results ; nonetheless, four out of nine
studies detected poorer performance in verbal mem-
ory in BD II patients. These discrepancies might be
due to the diﬀerent memory tasks used. Nevertheless,
other factors could explain these discrepant ﬁndings
such as the above-mentioned, history of psychoses or
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the presence of subclinical symptoms, among other
factors that require further research.
Visual memory
Visual memory has been assessed in eight studies. In
three of them BD II patients had a worse performance
than healthy subjects (Andersson et al. 2008 ; Dittmann
et al. 2008) or with respect to normative data (Summers
et al. 2006). In the study by Dittmann et al. (2008), both
BD I and BD II groups signiﬁcantly diﬀered from the
HC group but the two patient groups did not diﬀer
from each other. However, the ﬁndings reported by
Andersson et al. (2008) did not reﬂect important func-
tional impairment since the diﬀerence did not exceed
0.5 S.D. below the normative mean.
In contrast, ﬁve studies did not detect impaired
visual memory in BD II patients (Harkavy-Friedman
et al. 2006 ; Taylor Tavares et al. 2007 ; Holmes et al.
2008 ; Savitz et al. 2008 ; Hsiao et al. 2009). Savitz et al.
(2008) suggested that verbal and, perhaps, visual recall
deﬁcits distinguish BD I patients from individuals
with bipolar spectrum disorders. However, in two of
them, BD I patients also did not diﬀer from the HC
group in visual memory (Harkavy-Friedman et al.
2006 ; Hsiao et al. 2009).
Only three out of eight studies detected visual
memory deﬁcits in BD II patients. Therefore, the visual
memory impairment, if conﬁrmed, would be relatively
small, and may depend on factors such as mild de-
pressive symptoms or prior history of psychotic
symptoms.
Executive functions and working memory
Working memory
Most of the studies reported that the working memory
and executive function domain is impaired in BD II
patients. In studies with samples formed of euthymic
patients or patients with mild or residual symptoma-
tology, deﬁcits in some working memory measures
were detected (Summers et al. 2006 ; Torrent et al. 2006 ;
Andersson et al. 2008 ; Dittmann et al. 2008 ; Simonsen
et al. 2008 ; Hsiao et al. 2009). In this regard, Summers
et al. (2006) found that BD II patients were signiﬁcantly
more impaired than BD I patients. Moreover, in a
sample of depressed BD I and BD II suicide attem-
pters, a poorer working memory performance was
observed in BD II in two measures while BD I patients
presented poorer performance only in one measure
when compared with HCs (Harkavy-Friedman et al.
2006).
On the other hand, two studies failed to ﬁnd im-
paired working memory in depressed BD II patients
(Taylor Tavares et al. 2007 ; Holmes et al. 2008) as well
as a study assessing euthymic patients (Savitz et al.
2008).
In summary, six studies found impaired working
memory while three of them failed to detect it ; there-
fore, we can hypothesize that a working memory
deﬁcit may be one of the features of cognitive dys-
function associated with BD II.
Verbal ﬂuency
Regarding phonemic verbal ﬂuency, ﬁve out of six
studies did not ﬁnd a deﬁcit in BD II patients
(Summers et al. 2006 ; Torrent et al. 2006 ; Andersson
et al. 2008 ; Savitz et al. 2008 ; Simonsen et al. 2008),
while Harkavy-Friedman et al. (2006) pointed out that
BD II patients had a worse performance than HC
subjects in this task. It is also important to underline
that BD II subjects in the latter study were depressed,
so this ﬁnding may be related to ﬁndings reported by
Martı´nez-Ara´n et al. (2002, 2004b) where the only sig-
niﬁcant diﬀerence between euthymic patients and de-
pressed patients was observed in verbal ﬂuency,
suggesting that performance in the phonemic ﬂuency
task may be state-dependent.
Three studies examined semantic verbal ﬂuency
and two of them found that both BD I and BD II par-
ticipants performed worse than HCs (Torrent et al.
2006 ; Simonsen et al. 2008). On the other hand, one
study showed that only BD I patients performed
worse than controls and BD II patients did not sig-
niﬁcantly diﬀer from both BD I and HC groups
(Dittmann et al. 2008).
Cognitive ﬂexibility
The Wisconsin Card Sorting Test measures executive
function, especially concept formation and cognitive
ﬂexibility. Three studies using this test did not ﬁnd
impaired BD II patients (Summers et al. 2006 ; Torrent
et al. 2006 ; Savitz et al. 2008). However, Torrent et al.
(2006) found that BD II patients, as well as BD I
patients, showed a trend towards a higher number of
perseverative errors compared with HCs, which may
also be related to greater impulsivity. In two studies,
cognitive ﬂexibility was evaluated with another
measure, the Intra-Dimensional/Extra-Dimensional
Set-Shift subtest from CANTAB, with contradictory
results ; one of them found that unmedicated BD II
depressed subjects demonstrated intact performance
(Taylor Tavares et al. 2007) and the other found that
BD II patients scored signiﬁcantly lower than BD I
patients (Summers et al. 2006).
The TMT Test B (TMT-B) is used as a cognitive
ﬂexibility measure as well as a working memory
measure. Three studies out of ﬁve did not ﬁnd
diﬀerences between the BD II and HC groups
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(Harkavy-Friedman et al. 2006 ; Torrent et al. 2006 ;
Hsiao et al. 2009). In the study by Summers et al. (2006)
BD II patients were not impaired with respect to the
normative data on the TMT-B, although they scored
signiﬁcantly lower than BD I participants on this
measure. On the other hand, in the sample of
Dittmann et al. (2008) BD II patients performed sig-
niﬁcantly poorer than the HC group in this measure,
although BD I patients did not diﬀer from both
groups. However, in the study by Torrent et al. (2006),
although no signiﬁcant diﬀerences were found, a
trend towards a poorer performance was detected in
both BD subtypes when compared with HCs.
Overall, probably there is a decrease of cognitive
ﬂexibility in BD II.
Inhibitory control
The Stroop Colour and Word Test (SCWT) is a
measure of selective attention, but the interference
measure on the SCWT is usually considered a cogni-
tive ﬂexibility and, therefore, executive function
measure. Three out of four studies found that BD II
participants had a signiﬁcantly poorer performance
than the HC group (Torrent et al. 2006 ; Andersson et al.
2008 ; Simonsen et al. 2008). In one of them, both BD I
and BD II groups did not diﬀer signiﬁcantly among
each other (Simonsen et al. 2008) and in another the BD
II patients showed an intermediate level of perform-
ance between the BD I and control group (Torrent et al.
2006). Another study, detected as well that the BD II
group was impaired with respect to normative data
regarding this measure and scored signiﬁcantly lower
than the BD I group as well (Summers et al. 2006).
In summary, all studies reported impaired inhibi-
tory control as measured by the SCWT in BD II.
Other neuropsychological domains
Motor functioning
One study assessed motor functioning by the per-
formance of two tasks (Harkavy-Friedman et al. 2006).
In the Finger Tapping Test, no diﬀerences were de-
tected between the BD I, BD II and HC groups, but
depressed BD II patients performed signiﬁcantly
worse than BD I patients and HC subjects on a simple
motor task.
Another study (Berns et al. 2002) failed to ﬁnd dif-
ferences in a reaction time task between euthymic
BD II and HC subjects, but diﬀerent brain responses
when performing novel motor–spatial sequences were
shown. The authors suggested that the adaptation to a
novel sequence occurs by diﬀerent mechanisms in
patients, with a widespread medial prefrontal and
limbic activation. However, the lack of a BD I group
made it impossible to know whether both subtypes
had a similar activation of brain areas.
Motor functioning is a neglected domain, so future
studies should focus on it, also given the task sim-
plicity and compatibility with concomitant brain
imaging analysis.
Visual/constructional abilities
Only one study (Dittmann et al. 2008) evaluated this
domain and found that BD II patients showed signiﬁ-
cant deﬁcits in this cognitive function compared with
HC subjects, while BD I patients did not diﬀer from
any of the groups.
Aﬀective processing
In a study by Holmes et al. (2008), the medicated BD
group exhibited greater response latency than un-
medicated BD and healthy subjects and made more
omission errors during the happy condition than in
the sad condition in an aﬀective processing task, in-
dicating a potential attentional bias in subjects with
bipolar depression on mood-stabilizing medications.
The sample included both depressed BD I and BD II
participants ; however, additional tests were run after
omitting BD I subjects to determine the impact of this
smaller group without altering the results. The authors
consider that aﬀective blunting may occur as a result
of treatment with mood-stabilizing medications. In
another study (Summers et al. 2006), BDpatients under-
performed with respect to normative data in accuracy
on the expression of surprise and there were no
signiﬁcant diﬀerences between the BD I and BD II
groups. Patients with residual depression were less
sensitive to expressions of happiness and anger than
euthymic patients. They suggested that a poor emo-
tion processing in these patients is due to depression-
related cognitive deﬁcits. On the other hand, Derntl
et al. (2009) observed a reduced emotion recognition
performance in BD I but not BD II patients. BD I par-
ticipants tended to misinterpret especially sadness as
fear. These results were not correlated with either re-
sidual symptoms or other various clinical character-
istics.
Although these studies reported diﬀerences in
the emotion to which the BD patients are biased in
aﬀective processing, they support the notion that BD
patients are impaired in recognizing emotions, re-
gardless of diagnostic subtype.
Discussion
There is a paucity of studies addressing cognitive
deﬁcits in BD II, even more so regarding patients in
euthymia. The latter are more suitable in order to
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evaluate the magnitude and the permanence of cog-
nitive disturbance. Furthermore, methodological dif-
ferences exist regarding comparative groups, such as
heterogeneity of samples or inclusion of diﬀerent
mood states of the illness, for instance, making it dif-
ﬁcult to draw conclusions. Some of the studies evalu-
ated diﬀerences in neuropsychological performance
between BD I and BD II ; other studies compared de-
pressed BD II patients with major depressive disorder ;
further studies focused on the comparison with other
bipolar spectrum patients. Small sample-sized studies,
especially regarding BD II patients, might have deter-
mined type I or type II errors, so larger samples should
be analysed in order to reach ﬁrmer conclusions. Some
studies were conducted in unmedicated patients, since
treatments may play an important role in cognitive
deﬁcits, although available data regarding the eﬀects
of mood-stabilizers on cognition are inconsistent,
possibly due to methodological issues (Goldberg &
Chengappa, 2009 ; Vieta, 2009 ; Balanza´-Martı´nez et al.
2010). The cognitive deﬁcits observed in BD are not
simply the eﬀect of medication since these same cog-
nitive deﬁcits have been observed in unaﬀected re-
latives (Arts et al. 2008 ; Bora et al. 2009). There is also a
lack of consensus on neuropsychological tasks that
assess diﬀerent cognitive functions and the classiﬁ-
cation of tasks included under each cognitive domain;
the same cognitive task may be used as a measure
of diﬀerent cognitive domains in diﬀerent studies,
because the performance in most tests involves
more than one cognitive process. Depending on the
classiﬁcation of the neuropsychological measures on
the diﬀerent neurocognitive domains, the results of
meta-analyses or systematic reviews may vary. The
literature has suggested an association between cog-
nitive impairment and several clinical factors, such
as residual aﬀective symptoms, number and subtype
of episodes, age at illness onset and number of
admissions (Martı´nez-Ara´n et al. 2004a, b). Neverthe-
less, there are other important clinical factors related
to worse cognitive functioning that have not been
systematically investigated. Table 2 summarizes the
methodological issues of comparative studies regard-
ing the role of factors involved in cognition.
Regarding the selected studies, some of them con-
clude that there are no essential diﬀerences in neuro-
psychological proﬁles between BD I and BD II patients
(Dittmann et al. 2008). In the above-mentioned study,
BD I patients showed signiﬁcantly lower scores in
psychomotor speed, working memory, verbal learn-
ing, delayed memory and executive functions than
HCs, while BD II patients showed signiﬁcant deﬁcits
in psychomotor speed, working memory, visual/
constructional abilities and executive functions, but
not on verbal learning and delayed memory. No sig-
niﬁcant diﬀerences among clinical groups were de-
tected on any tested domain, supporting a similar
pattern of cognitive deﬁcits.
Other studies found that BD II patients had an in-
termediate level of performance between BD I and HC
groups in verbal memory (Martı´nez-Ara´n et al. 2004b ;
Torrent et al. 2006) and executive functions (Torrent
et al. 2006). Similarly, some authors suggest that BD I
patients have more widespread cognitive dysfunction
than BD II patients (Simonsen et al. 2008 ; Hsiao et al.
2009). In the study by Simonsen et al. (2008) BD II
patients showed reduced performance on certain
measures of attention and executive function (working
memory, verbal ﬂuency and interference control),
while the BD I group showed reduced performance on
all verbal memory measures and on most measures of
attention and executive function (working memory,
ﬂuency, interference control and set-shifting). More-
over, a higher proportion of BD I patients had clini-
cally signiﬁcant cognitive impairment compared with
BD II patients, and they concluded that both groups
Table 2. Methodological issues of comparative studies on cognition : role of factors involved in cognition
 No consistent results about the eﬀect of pharmacological treatment on cognition. There is a lack of control due to
polypharmacy
 Subclinical aﬀective symptoms may have an impact on cognitive functioninga. Some studies do not control statistically
this variable
 History of psychosis may partly account for the cognitive dysfunction even when controlling for bipolar diagnostic
subtypeb,c
 Childhood trauma has been reported to inﬂuence cognition negativelyd. It might be important to control for. Other factors
to control for are factors related to prenatal development and obstetric complicationse, and factors associated with the
neurodevelopmental process in general
 Potentially confounding variables in neuropsychological analyses are co-morbid alcohol abusef, attention
deﬁcit/hyperactivity disorderg,h,i and other co-morbid conditions
aMartı´nez-Ara´n et al. (2000). b Martı´nez-Ara´n et al. (2008). c Simonsen et al. (2011). d Savitz et al. (2008). e Martino et al. (2009).
f Sa´nchez-Moreno et al. (2009). g Pavuluri et al. (2006). h Henin et al. (2007). i Rucklidge (2006).
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have diﬀerent neurocognitive proﬁles. In the study
by Hsiao et al. (2009), while BD II patients showed a
reduction only in working memory and psychomotor
speed, BD I patients also showed a reduction in verbal
memory and executive function.
Nevertheless, two studies suggest that cognitive
deﬁcits are more severe and pervasive in BD II than
BD I patients (Harkavy-Friedman et al. 2006 ; Summers
et al. 2006). In the study by Summers et al. (2006),
whereas the BD I group was only impaired in verbal
recognition and spatial working memory, the BD II
group was also impaired in these measures and ad-
ditionally in other memory and executive measures.
These authors point out that recurrent depressive
episodes, rather than mania, may have a more detri-
mental and lasting eﬀect on cognition. Regarding the
study conducted by Harkavy-Friedman et al. (2006),
their sample of BD II patients may represent a greater
severity of illness than those with BD II who have
never committed a suicide attempt ; however, they
suggested that BD II is a serious disorder with a
distinguishing pattern of neuropsychological func-
tioning.
Finally, two studies failed to ﬁnd deﬁcits in the BD
II group. The ﬁrst study found that unmedicated
depressed BD II subjects displayed relatively intact
cognitive function (Taylor Tavares et al. 2007). The
latter found that BD II patients did not diﬀer signiﬁ-
cantly from their unaﬀected relatives, whereas BD I
patients showed impaired verbal memory (Savitz et al.
2008). However, the sample size of BD II patients in
these two studies was relatively small.
Noteworthy, also, is the study by Andersson et al.
(2008), where performance of BD II patients was
signiﬁcantly worse than that of HCs on all measures,
except for phonemic verbal ﬂuency. These authors
discussed the functional signiﬁcance of neuropsycho-
logical impairment and suggested that diﬀerences
regarding some aspects of executive function may be
related to psychomotor speed, and not primarily to
dysexecutive functioning, taking into consideration
their ﬁndings in electrophysiological index.
Therefore, the results of these studies are inconsist-
ent, possibly due to diﬀerent methodologies used.
For example, a factor that may predispose to a greater
cognitive dysfunction in BD II than BD I is the
increased prevalence of subclinical depressive symp-
toms in BD II (Benazzi, 2001). Despite the scarcity
of studies, the neuropsychological proﬁles of both
diagnostic subtypes are diﬀerent and, except for two
studies, all of them detected cognitive deﬁcits in BD II.
The main ﬁndings include impaired working memory
and some measures of executive functions (inhibitory
control) and approximately half of the studies also
detect verbal memory impairment.
Underlying mechanisms for diﬀerences in cognitive
functioning between the two diagnostic subtypes
could be due to either variations in frequency and
severity of symptoms, as well as residual depressive
symptoms, or to diﬀerent genetic liability (Dittmann
et al. 2008), or these may indicate neurobiological dif-
ferences (Simonsen et al. 2008). These ﬁndings show-
ing distinct cognitive proﬁles in both subtypes could
lead to better identiﬁcation of cognitive endo-
phenotypes in BD. BD I would be nearer schizo-
phrenia and BD II would show a lesser degree of
cognitive impairment, reﬂecting the idea of a con-
tinuum in the psychoses (Torrent et al. 2006 ; Martı´nez-
Ara´n et al. 2008).
Future directions
Future studies should routinely assess cognitive
functioning in euthymic patients with both subtypes
of BD. Furthermore, large samples are to be highly
recommended. One implication arising from this re-
view is that future neurocognitive research needs to
focus on individuals with BD and concomitant history
of psychosis separately from those without a history of
psychosis in order to study the impact of this variable
on neuropsychological performance. Similarly to the
above-mentioned study by Simonsen et al. (2011),
Martı´nez-Ara´n et al. (2008) also suggested that the
history of psychosis may partly account for the cogni-
tive dysfunction seen in euthymic patients, especially
with regard to persistent verbal memory dysfunction
as well as some executive dysfunctions. Future studies
should take into account residual symptoms, which
are not frequently measured, since these might
possibly explain some persistent cognitive deﬁcits
(Martino et al. 2009) ; furthermore a consensual deﬁ-
nition of subclinical symptoms is necessary (Daban
et al. 2006). Other variables to consider should be the
polarity of the last episode, predominant polarity and
the period of time from the last recurrence. Sustained
attention should be routinely assessed, since attention
is a function that inﬂuences other cognitive domains.
Motor functioning is another aspect to evaluate
(Balanza´-Martı´nez et al. 2008). In a recent study it was
suggested that motor speed may be a potential endo-
phenocognitype for both schizophrenia and BD I
patients (Salazar-Fraile et al. 2009). It is necessary to
reach a consensus on the most appropriate cognitive
tests for the assessment of cognitive impairment in BD,
in order to obtain comparable studies and replicate
ﬁndings.
Diﬀerentiation between BD I and BD II patients
will be helpful in order to determine cognitive
endophenotypes in BD. Findings on neurocognitive
diﬀerences between the two subtypes can be used as
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markers in research for underlying neurobiological
distinguishers using neuroimaging techniques. Neuro-
imaging and genetics might be useful in validating BD
II diagnostic subtype (Vieta & Suppes, 2008). Some
genetic studies have suggested that BD II and BD I
‘breed true’ in families ; therefore, in further studies
it would be interesting to correlate clinical and
neuropsychological data with genetic data in BD II
patients. Although this speciﬁc issue has not been ex-
tensively examined in this paper, focused basically on
cognition, it could be important to do so in a future
report.
Diﬀerences in cognitive dysfunction between both
subtypes may have an eﬀect on psychosocial func-
tioning, treatment adherence as well as the possibility
to beneﬁt from psychoeducational programmes.
Neurocognitive rehabilitation should consider diﬀer-
ences in cognitive proﬁles in order to design speciﬁc
programmes aiming to treat prevailing cognitive dys-
functions for each subtype.
According to the conclusions of this systematic re-
view, though still not clearly established, it appears
that there are subtle diﬀerences between BD I and BD
II regarding cognition ; deﬁcits in BD II subjects were
identiﬁed mainly in the areas of working memory,
inhibitory control and verbal memory as well. Now-
adays, BD II is classiﬁed as a distinct category within
mood disorders, but the deﬁnition and boundaries
deserve further clariﬁcation (Vieta & Suppes, 2008).
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